Research Funding
3 articles on Research Funding, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic, Wegovy, Mounjaro: Who Benefits When Obesity is Labeled a Disease?
As GLP-1 medications like Ozempic, Wegovy, and Mounjaro gain prominence, the medical community and pharmaceutical giants are increasingly framing obesity as a chronic disease. This article delves into the multifaceted implications of this classification, examining its impact on treatment, policy, and patient perception, while questioning who truly benefits from this shift.
7 min read
Eli Lilly Turns to AI After GLP-1 Boom for Next Growth
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
6 min read
A Peek Inside Dominic Cummings' Ambitious Lab Aiming for an 'Ozempic Moment'
Dominic Cummings' vision for a groundbreaking research agency is gaining momentum with cross-party support and substantial funding. ARIA aims to revolutionize the UK through cutting-edge technologies and entrepreneurial science, seeking its own 'Ozempic moment'.
5 min read